Media Alert
Boston Scientific announces new developments in its Electrophysiology portfolio

Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently, the first ever patient in Europe was treated with the new innovative RHYTHMIA™ Mapping System at Hammersmith Hospital in London. The RHYTHMIA™ System uses state-of-the-art 3-D technology to collect thousands of relevant data points in only a few minutes, providing Electro physiologists with high-resolution electro-anatomical maps for use in the treatment of heart rhythm disorders.

This milestone procedure follows the inclusion of the S-ICD™ System in the recent ESC guidelines on hypertrophic cardiomyopathy (HCM), as a first-line treatment option in patients at risk of sudden cardiac arrest.  Trudie Lobban, Founder and CEO of Arrhythmia Alliance, commented:

“With 75,000 to 100,000 lives lost to sudden cardiac arrest each year in the UK, there is a strong need to ensure that people suffering from arrhythmia have access to innovative medical devices like the S-ICD™ System.  We welcome the inclusion of the S-ICD™ System in the recent ESC guidelines on hypertrophic cardiomyopathy (HCM), and it is important that we continue to work with stakeholders to ensure people suffering from arrhythmia in the UK benefit from this life-saving device. There is also a need to improve diagnosis and shorten procedure times in patients with complicated heart rhythm disorders.  Innovations like the RHYTHMIA™ Mapping System which improves patient care whilst providing clinicians with more accurate and detailed information are particularly welcome.  We are delighted to hear that the first patient in Europe was recently treated with the RHYTHMIA™ Mapping System and we will work to ensure as many people benefit from this unique system as possible”.  

These developments come ahead of the 2014 Heart Rhythm Congress in Birmingham on 5-8 October 2014, where leading cardiologists and professionals in cardiology will be discussing the significant benefits of these devices and the latest innovations in heart rhythm management.

We are happy to facilitate a 1:1 onsite, phone or e-mail interview, with the following three experts, who can talk about the benefits of innovative technology such as the RHYTHMIA™ System and the S-ICD™ System:

• Dr. Wyn Davies, Consultant Cardiologist from Imperial College Healthcare NHS Trust, who performed the procedure with the RHYTHMIA™ System at Hammersmith  Hospital
• Pierre Chauvineau, VP Cardiac Rhythm Management Europe at Boston Scientific
• Trudie Lobban, Founder and CEO of Arrhythmia Alliance

More information on Boston Scientific’s Electrophysiology (EP) portfolio is available at news.bostonscientific.eu. This will shortly be supplemented with additional EP press materials so please do check back regularly.

Should you have any questions or would like to receive additional information on Boston Scientific’s presence at the Heart Rhythm Congress, please do not hesitate to contact Mary Hinks-Edwards on +44 7786 335 819.